ReviewPediatric nephrology (Berlin, Germany)2004
Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?
Review in Pediatric nephrology (Berlin, Germany), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.Pediatric nephrology (Berlin, Germany) · 2006Trial
- Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.Internal and emergency medicine · 2021Article
- Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose.Chinese journal of integrative medicine · 2014Article
- Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2013Article
- The growing epidemic of hypertension among children and adolescents: a challenging road ahead.Pediatric cardiology · 2012Review
- Microalbuminuria and early renal response to lethal dose Shiga toxin type 2 in rats.International journal of nephrology and renovascular disease · 2012Article
- Chronic kidney disease: highlights for the general pediatrician.International journal of pediatrics · 2012Article
- Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2010Review
- Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2009Article
- Progression of glomerular and tubular disease in pediatrics.Seminars in nephrology · 2009Review
- Nephrotoxicity as a cause of acute kidney injury in children.Pediatric nephrology (Berlin, Germany) · 2008Review
- How have the past 5 years of research changed clinical practice in paediatric nephrology?Archives of disease in childhood · 2007Review
- Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management.Paediatric drugs · 2007Review
- The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals.European journal of clinical pharmacology · 2007Article
- Prescription of drugs blocking the renin-angiotensin system in Italian children.Pediatric nephrology (Berlin, Germany) · 2007Article
- Prognostic significance of microalbuminuria in postdiarrheal hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Article
- Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan.Pediatric nephrology (Berlin, Germany) · 2006Article
- Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation.International journal of hematology · 2006Article
- The role of calcium antagonists in patients with chronic renal failure.Pediatric nephrology (Berlin, Germany) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We discuss the evidence supporting the use of angiotensin-converting enzyme inhibitors (ACEI), angiotensin II type 1 receptor blockers (ARB), or the combination of both in children with chronic renal disease. Several large-scale, prospective, randomized studies with clinical end points have been performed in adult patients, but studies in children are relatively scarce. In adult patients with chronic renal diseases, ACEI clearly delay the progression of chronic non-diabetic renal diseases, and nephropathy in patients with type 1 diabetes. The benefits of ACEI are most apparent in glomerular diseases with marked proteinuria but extend also to kidney diseases with lower proteinuria. This notion is also supported by several smaller or retrospective trials in children. Therefore, ACEI should be given to children with chronic renal diseases, particularly if high blood pressure and/or proteinuria are present. In adults, large-scale trials have documented that ARB exert similar effects as ACEI but tend to exert fewer undesired side effects. Data on ARB in children with chronic renal disease are still very scarce, but these substances offer an alternative for patients who cannot tolerate ACEI due to unwarranted side effects. Combination therapy with ARB plus ACEI may be more effective than either drug class alone. However, we will need the results of further long-term prospective clinical studies, as well as a better understanding of the role of the AT(2) receptor, before combination therapy can be widely recommended. A trial of ARB plus ACEI is justified in selected patients if blood pressure and/or proteinuria cannot adequately be lowered by ACEI or ARB alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.